What ACell does

ACell was a Columbia, Maryland-based regenerative medicine company founded in 1999 by Alan R. Spievack, a former associate professor at Harvard Medical School whose research on salamander regeneration and extracellular matrices led to the development of the company's core Urinary Bladder Matrix (UBM) technology. UBM is a biologically-derived, three-dimensional extracellular matrix scaffold manufactured from porcine urinary bladder through minimal processing that preserves collagens, laminin, proteoglycans, and growth factors; the resulting devices are non-crosslinked, resorbable, and decellularized, and are designed to be fully remodeled into host tissue without leaving a foreign body.

The product portfolio is built around two clinical use cases. The Cytal family (Cytal Wound Matrix and Cytal Burn Matrix) delivers UBM in sheet form for wound management, while MicroMatrix UBM Particulate (and MicroMatrix Flex, a dual-syringe delivery system) provides UBM in particulate form for complex and hard-to-reach wounds. The Gentrix Surgical Matrix family, including Hiatal, Plus, Thick, and Thin variants, is intended for soft tissue reinforcement in hernia repair and gastroenterological, abdominal wall, and plastic and reconstructive surgery. The platform is supported by over 200 pre-clinical and clinical publications and has been in the marketplace for more than 10 years.

ACell was acquired by Integra LifeSciences Holdings Corporation in January 2021 and now operates as part of Integra's regenerative medicine portfolio. Products are sold through Integra's enterprise sales organization to hospitals, surgical centers, and healthcare providers; pricing is not publicly disclosed. A separate UBM veterinary portfolio is distributed via Integra Veterinary.

Name

ACell

Legal name

ACell

Website

https://acell.com

Company type

Private

Founded year

1999

Operating status

Acquired

Headcount range

251–500 employees

Short description

ACell developed proprietary Urinary Bladder Matrix (UBM) extracellular matrix scaffolds for wound management and soft tissue reinforcement, serving hospitals, burn centers, and surgical specialists before its January 2021 acquisition by Integra LifeSciences.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Acellular/Decellularized Matrices & ECM Products (HLAAAGAF), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Regenerative medicine devices
• Extracellular matrix scaffolds
• Wound management products
• Soft tissue reinforcement
• Biologic surgical matrices

Headquarters

HQ city

Columbia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

ACell develops, manufactures, and markets Urinary Bladder Matrix (UBM) biologic devices — extracellular matrix scaffolds derived from porcine urinary bladder — used for wound management and soft tissue reinforcement in surgical applications. Its portfolio includes the Cytal sheet-form matrices, MicroMatrix particulate forms, and Gentrix surgical matrices for hernia repair and reconstructive surgery. The devices are biologically-derived, non-crosslinked, resorbable, and decellularized, supporting tissue remodeling through M2 macrophage modulation.

Product overview

ACell is a regenerative medicine company specializing in Urinary Bladder Matrix (UBM) technology, an extracellular matrix scaffold platform derived from porcine urinary bladder. The portfolio, acquired by Integra LifeSciences in 2021, consists of two main product families: the Cytal Wound/Burn Matrix (sheet forms) and MicroMatrix UBM Particulate/Flex (particulate forms) for wound management, and the Gentrix Surgical Matrix family (including Hiatal, Plus, Thick, and Thin variants) for soft tissue reinforcement in gastroenterological and plastic/reconstructive surgeries. All products are biologically-derived, non-crosslinked, resorbable, and decellularized scaffolds that support site-appropriate tissue remodeling.

Differentiator

Problem solved

Functional benefit

Brands

• Cytal: Sheet form of UBM Technology intended for wound management, available in various sizes and thicknesses. Includes Cytal Wound Matrix and Cytal Burn Matrix.
• MicroMatrix
• Gentrix

Products and services

• Cytal Wound Matrix Sheet form of Urinary Bladder Matrix (UBM) technology intended for wound management. Biologically-derived, non-crosslinked, resorbable, decellularized extracellular matrix scaffold available in a variety of sizes and thicknesses. For healthcare providers managing complex wounds.
• Cytal Burn Matrix
• MicroMatrix UBM Particulate
• MicroMatrix Flex
• Gentrix Surgical Matrix

Quantifiable outcome

• UBM devices fully resorb and completely remodel into host tissue, leaving no foreign body
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Integra LifeSciencescoreStrategic or Co-development Partner · 1 January 2021Integra LifeSciences completed the acquisition of ACell in January 2021. The acquisition brought ACell's Urinary Bladder Matrix (UBM) technology platform into Integra's portfolio, which includes Cytal Wound Matrix, Cytal Burn Matrix, MicroMatrix UBM Particulate, MicroMatrix Flex, and Gentrix Surgical Matrix products.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Smith & Nephew: Smith & Nephew's Advanced Wound Management portfolio (including ALLEVYN, PICO, and bioactives) competes with ACell's wound care products across hospital and community care settings, with a much broader portfolio and global commercial footprint.
• Mölnlycke Health Care: Mölnlycke is a global wound care and surgical solutions leader whose Mepilex, Mepitel, and Avance biologics portfolios compete with ACell's UBM products in both chronic wound management and surgical reinforcement applications.
• Becton, Dickinson and Company (BD): BD's Surgery unit (formerly Bard) offers biologic and synthetic hernia repair meshes that compete with ACell's Gentrix Surgical Matrix family in soft tissue reinforcement and hernia repair procedures.
• Integra LifeSciences: Integra LifeSciences acquired ACell in January 2021 and now markets the UBM product line as part of its regenerative medicine portfolio alongside DuraGen and other collagen-based matrices, making it both parent and adjacent portfolio peer.
• ConvaTec: ConvaTec is a global advanced wound care and ostomy incumbent whose portfolio (AQUACEL, Foam Lite, and regenerative biologic adjuncts) competes with ACell's wound care franchise, particularly in chronic and surgical wound applications.
• Ethicon (Johnson & Johnson MedTech): Ethicon is the global market leader in hernia repair and soft tissue reinforcement products (Proceed, Physiomesh, and newer biologic portfolios) and competes directly with ACell's Gentrix Surgical Matrix franchise in abdominal wall and hiatal hernia repair.
• Coloplast: Coloplast's Wound & Skin Care division offers a broad portfolio of advanced wound dressings and biologics (including the recent Kerecis acquisition), competing with ACell's Cytal and MicroMatrix products in advanced wound care.

Direct peers

• MiMedx Group: MiMedx is the leading US distributor of regenerative wound care and surgical recovery products, including EpiFix (dehydrated human amnion/chorion membrane) and AmnioFix, competing directly with ACell's Cytal Wound Matrix and MicroMatrix in the advanced wound care and surgical application channels.
• Organogenesis: Organogenesis markets Apligraf and Dermagraft, two of the most established bioengineered skin substitutes for chronic wound care, directly competing with ACell's UBM-based Cytal and MicroMatrix products in the advanced wound care market.

Emerging players

• CorMatrix (Cor Cardiovascular): CorMatrix developed extracellular matrix (ECM) bioscaffold technology derived from porcine small intestinal submucosa for cardiac and soft tissue repair, offering a directly comparable ECM platform to ACell's UBM, though with a narrower commercial footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/acell-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACell